tirzepatide vs semaglutide appetite suppression Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide vs. Tirzepatide for Weight
Description
Imeryz N, Yeen B, Bozkurt A, Cokun T, Villanueva-Peacarrillo ML, Ulusoy NB
Retrieved May 13, 2022, from [2] FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
Both are administered as weekly subcutaneous injections
Aronne LJ, Sattar N, Horn DB, et al
We will guide you on the proper technique for self- administration
Extended data Extended Data Fig
